Characterization of dengue virus complex-specific neutralizing epitopes on envelope protein domain III of dengue 2 virus

被引:144
作者
Gromowski, Gregory D. [1 ,2 ]
Barrett, Nicholas D. [3 ]
Barrett, Alan D. T. [1 ,2 ]
机构
[1] Univ Texas Med Branch, Dept Pathol, Sealy Ctr Vaccine Dev, Ctr Biodef & Emerging Infect Dis, Galveston, TX 77555 USA
[2] Univ Texas Med Branch, Inst Human Infect & Immun, Galveston, TX 77555 USA
[3] Univ Texas Austin, Sch Nat Sci, Austin, TX 78712 USA
关键词
D O I
10.1128/JVI.00606-08
中图分类号
Q93 [微生物学];
学科分类号
071005 [微生物学]; 100705 [微生物与生化药学];
摘要
The surface of the mature dengue virus (DENV) particle is covered with 180 envelope (E) proteins arranged as homodimers that lie relatively flat on the virion surface. Each monomer consists of three domains (ED1, ED2, and ED3), of which ED3 contains the critical neutralization determinant(s). In this study, a large panel of DENV-2 recombinant ED3 mutant proteins was used to physically and biologically map the epitopes of five DENV complex-specific monoclonal antibodies (MAbs). All five MAbs recognized a single antigenic site that includes residues K310, I312, P332, L389, and W391. The DENV complex antigenic site was located on an upper lateral surface of ED3 that was distinct but overlapped with a previously described DENV-2 type-specific antigenic site on ED3. The DENV complex-specific MAbs required significantly higher occupancy levels of available ED3 binding sites on the virion, compared to DENV-2 type-specific MAbs, in order to neutralize virus infectivity. Additionally, there was a great deal of variability in the neutralization efficacy of the DENV complex-specific MAbs with representative strains of the four DENVs. Overall, the differences in physical binding and potency of neutralization observed between DENV complex- and type-specific MAbs in this study demonstrate the critical role of the DENV type-specific antibodies in the neutralization of virus infectivity.
引用
收藏
页码:8828 / 8837
页数:10
相关论文
共 35 条
[1]
The envelope glycoprotein domain III of dengue virus serotypes 1 and 2 inhibit virus entry [J].
Chin, J. F. L. ;
Chu, J. J. H. ;
Ng, M. L. .
MICROBES AND INFECTION, 2007, 9 (01) :1-6
[2]
Inhibition of West Nile virus entry by using a recombinant domain III from the envelope glycoprotein [J].
Chu, JJH ;
Rajamanonmani, R ;
Li, J ;
Bhuvanakantham, R ;
Lescar, J ;
Ng, ML .
JOURNAL OF GENERAL VIROLOGY, 2005, 86 :405-412
[3]
Monoclonal antibodies that bind to domain III of dengue virus E glycoprotein are the most efficient blockers of virus adsorption to Vero cells [J].
Crill, WD ;
Roehrig, JT .
JOURNAL OF VIROLOGY, 2001, 75 (16) :7769-7773
[4]
IDENTIFICATION OF DISTINCT ANTIGENIC DETERMINANTS ON DENGUE-2 VIRUS USING MONOCLONAL-ANTIBODIES [J].
GENTRY, MK ;
HENCHAL, EA ;
MCCOWN, JM ;
BRANDT, WE ;
DALRYMPLE, JM .
AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 1982, 31 (03) :548-555
[5]
A NEW MECHANISM FOR THE NEUTRALIZATION OF ENVELOPED VIRUSES BY ANTIVIRAL ANTIBODY [J].
GOLLINS, SW ;
PORTERFIELD, JS .
NATURE, 1986, 321 (6067) :244-246
[6]
Characterization of an antigenic site that contains a dominant, type-specific neutralization determinant on the envelope protein domain III (ED3) of dengue 2 virus [J].
Gromowski, Gregory D. ;
Barrett, Alan D. T. .
VIROLOGY, 2007, 366 (02) :349-360
[7]
HALSTEAD SB, 1988, SCIENCE, V239, P476, DOI 10.1126/science.3277268
[8]
ANTIBODIES THAT BLOCK VIRUS ATTACHMENT TO VERO CELLS ARE A MAJOR COMPONENT OF THE HUMAN NEUTRALIZING ANTIBODY-RESPONSE AGAINST DENGUE VIRUS TYPE-2 [J].
HE, RT ;
INNIS, BL ;
NISALAK, A ;
USAWATTANAKUL, W ;
WANG, SL ;
KALAYANAROOJ, S ;
ANDERSON, R .
JOURNAL OF MEDICAL VIROLOGY, 1995, 45 (04) :451-461
[9]
EPITOPIC ANALYSIS OF ANTIGENIC DETERMINANTS ON THE SURFACE OF DENGUE-2 VIRIONS USING MONOCLONAL-ANTIBODIES [J].
HENCHAL, EA ;
MCCOWN, JM ;
BURKE, DS ;
SEGUIN, MC ;
BRANDT, WE .
AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 1985, 34 (01) :162-169
[10]
Mutational analysis of a neutralization epitope on the dengue type 2 virus (DEN2) envelope protein: Monoclonal antibody resistant DEN2/DEN4 chimeras exhibit reduced mouse neurovirulence [J].
Hiramatsu, K ;
Tadano, M ;
Men, R ;
Lai, CJ .
VIROLOGY, 1996, 224 (02) :437-445